氮卓斯汀联合氟替卡松治疗变应性鼻炎的临床观察

发布时间：2018-01-23 19:06

本文关键词： 变应性鼻炎氮卓斯汀氟替卡松鼻通气障碍　出处：《中国药房》2017年23期 　论文类型：期刊论文

【摘要】：目的:观察氮卓斯汀联合氟替卡松治疗变应性鼻炎(AR)的有效性及安全性。方法:选择2015年1月-2016年7月笔者所在3家医院中的AR患者135例作为研究对象,按随机数字表法分为氮卓斯汀组、氟替卡松组和联合用药组,各45例。在给予减充血剂盐酸羟甲唑啉喷雾剂的基础上,氮卓斯汀组患者给予盐酸氮卓斯汀鼻喷剂,每个鼻孔1喷,早晚各1次;氟替卡松组患者给予丙酸氟替卡松鼻喷雾剂,每个鼻孔1喷,早晚各1次;联合用药组患者给予盐酸氮卓斯汀鼻喷剂联合丙酸氟替卡松鼻喷雾剂,用法用量同前。3组患者均持续用药30 d。比较3组患者的鼻部症状总评分(TNSS)和眼部症状总评分(TOSS)下降指数、鼻腔最小横截面积(NMCA)、鼻腔总阻力(TNR),以及不良反应发生情况。结果:试验过程中因不同原因脱落,剩余127例患者进入全分析数据集、130例患者进入安全数据集。治疗后,联合用药组患者的TNSS下降指数明显高于氮卓斯汀组和氟替卡松组,差异均有统计学意义(P0.05);氮卓斯汀组与氟替卡松组患者的TNSS下降指数,以及3组患者的TOSS下降指数比较,差异均无统计学意义(P0.05)。治疗前,3组患者均有不同程度的鼻通气障碍,但TNR和NMCA比较差异均无统计学意义(P0.05);治疗后,3组患者的NMCA以及在75、150 Pa下的TNR均明显小于治疗前,且联合用药组的TNR明显小于氮卓斯汀组和氟替卡松组,差异均有统计学意义(P0.05);但3组患者间NMCA比较,差异无统计学意义(P0.05)。3组患者总不良反应发生率比较,差异无统计学意义(P0.05)。结论:氮卓斯汀和氟替卡松均可有效缓解AR患者的鼻部症状,改善鼻通气障碍;联合用药的疗效优于单一用药方案,而且并未增加不良反应的发生概率。
[Abstract]:Objective: to observe the effect of azostostine combined with fluticasone in the treatment of allergic rhinitis. Methods: from January 2015 to July 2016, 135 AR patients in 3 hospitals were selected as the study objects. According to the random digital table method, the patients were divided into three groups: azostostine group, fluticasone group and combined treatment group, each with 45 cases. The patients in the azostostine group were given azostostine hydrochloride nasal spray, 1 spray in each nostril, 1 time in the morning and evening. Patients in fluticasone group were given fluticasone propionate nasal spray, 1 spray per nostril, 1 time in the morning and evening. The patients in the combined treatment group were given azostostine hydrochloride nasal spray combined with fluticasone propionate nasal spray. The total nasal symptom score (TNSS) and the total ocular symptom score (TOSS) of the three groups were compared with those of the former group (30 days), and the decrease index of the total nasal symptom score (TNSS) and the total ocular symptom score (TOSS) were compared. The minimal cross sectional area of nasal cavity (NMCAA), total nasal resistance (TNRN), and adverse reactions occurred. Results: in the course of the trial, the remaining 127 patients were included in the total analysis data set due to different reasons. After treatment, the decrease index of TNSS in the combined treatment group was significantly higher than that in the azostostine group and fluticasone group, and the difference was statistically significant (P 0.05). Compared with fluticasone group and azostetin group, the decrease index of TNSS and TOSS of the three groups were not significantly different before treatment (P0. 05%, P 0. 05%, P 0. 05, P 0. 05, P 0. 05, P 0. 05, P < 0. 05). The three groups had different degree of nasal ventilation disorder, but the difference of TNR and NMCA was not statistically significant (P 0.05). After treatment, the NMCA and TNR at 75,150 Pa in the three groups were significantly lower than those before treatment, and the TNR in the combined treatment group was significantly lower than that in the azoxetine group and fluticasone group. The difference was statistically significant (P 0.05). However, there was no significant difference in NMCA among the three groups. Conclusion: azosteine and fluticasone can effectively relieve nasal symptoms and improve nasal ventilation disorders in AR patients. The efficacy of combined therapy was better than that of single regimen, and the probability of adverse reactions was not increased.
【作者单位】：河北医科大学第二医院耳鼻咽喉二科;石家庄市第一医院耳鼻喉科;石家庄市鹿泉人民医院儿科;
【分类号】：R765.21
【正文快照】： 变应性鼻炎(Allergic rhinitis,AR)是一种由免疫球蛋白E(Immunoglobulin E,Ig E)介导的炎症性疾病,以鼻塞、流涕、喷嚏、鼻痒等为主要症状[1]。临床对AR的治疗以糖皮质激素和抗组胺药物为主,其中抗组胺药物被推荐为治疗轻度AR的首选药物;而对于中、重度AR,临床常以糖皮质激素

【相似文献】